Brief: Tiziana Life Sciences Initiates Program To Develop Intranasal Foralumab In Type 1 Diabetes
18/04/2023 12:11
April 18 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES INITIATES PROGRAM TO DEVELOP
INTRANASAL
FORALUMAB IN TYPE 1 DIABETES
* TIZIANA LIFE SCIENCES - INITIATES PROGRAM TO STUDY
TREATMENT,
DELAY OF TYPE 1 DIABETES USING ITS CONVENIENT SELF-ADMINISTERED
INTRANASAL FORALUMAB
Source text for Eikon: ID:nGNX4MH1VM
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis